Highlights in lymphoma from the 2018 American Society of Clinical Oncology annual meeting.
Authors: PMID: 30300335 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - October 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in lymphoma from the 2018 American Society of Clinical Oncology annual meeting: commentary.
Authors: Chen RW PMID: 30300336 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - October 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Advances in aggressive lymphoma from the 2018 American Society of Clinical Oncology annual meeting.
Authors: PMID: 30300337 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - October 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Advances in aggressive lymphoma from the 2018 American Society of Clinical Oncology annual meeting: commentary.
Authors: Locke FL, Jain MD PMID: 30300338 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - October 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Clinical implications of the 2018 iwCLL Guidelines update.
Authors: O'Brien SM PMID: 30300339 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - October 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in chronic lymphocytic leukemia from the 23rd Congress of the European Hematology Association.
Authors: PMID: 30300340 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - October 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Refining the management of polycythemia vera.
Authors: Mesa RA PMID: 30256773 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 28, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Update on managing brain metastases in breast cancer.
Authors: Lin NU PMID: 30256774 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 28, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Diagnosis and management of dysfibrinogenemia.
Authors: Shapiro SE PMID: 30256775 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 28, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Dosing drugs in elderly patients with cancer.
Authors: Hurria A PMID: 30256776 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 28, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Changing local therapy in breast cancer: who needs what, and when?
Authors: Al-Zubeidy BH, Weiss H, Khan SA Abstract The local therapy of breast cancer continues to evolve toward less surgery. Breast conservation is firmly in place, with recent trends toward decreased rates of re-excision. Axillary dissection is becoming a rare operation and is being replaced by sentinel node biopsy. The switch to sentinel node biopsy occurred first in patients with pathologically tumor-free nodes, and later in patients with limited nodal disease. Sentinel node biopsy is now also widely used in patients with pathologically positive nodes who receive neoadjuvant chemotherapy. Axillary surgery is be...
Source: Clinical Advances in Hematology and Oncology - September 28, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Distinguishing autoimmune myelofibrosis from primary myelofibrosis.
Authors: Marcellino B, El Jamal SM, Mascarenhas JO Abstract Bone marrow fibrosis (BMF) is a histologic finding in a wide range of diseases, including malignancies, endocrine disorders, autoimmune diseases, and infections. Autoimmune myelofibrosis (AIMF) is an uncommon etiology of BMF; it can be secondary to a defined autoimmune disease, or it can be primary in the absence of a clinically diagnosed autoimmune disease but the presence of serologic evidence of autoantibodies. Distinguishing between primary myelofibrosis (PMF) and non-neoplastic AIMF is of the utmost importance because the prognosis and therapeutic opt...
Source: Clinical Advances in Hematology and Oncology - September 28, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in chronic lymphocytic leukemia from the 2018 American Society of Clinical Oncology annual meeting.
Authors: PMID: 30235179 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 22, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in chronic lymphocytic leukemia from the 2018 American Society of Clinical Oncology Annual Meeting: commentary.
Authors: O'Brien SM PMID: 30235180 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 22, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in breast cancer from the 2018 American Society of Clinical Oncology annual meeting.
Authors: Rugo HS PMID: 30148824 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 29, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Immunotherapy in the adjuvant setting for high-risk melanoma.
Authors: Weber JS PMID: 30148825 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 29, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Weight-based dosing vs fixed dosing of pembrolizumab: an economic analysis.
Authors: Goldstein D PMID: 30148826 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 29, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Chemoprevention of colorectal cancer: aspirin and beyond.
Authors: Limburg PJ PMID: 30148827 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 29, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Adjuvant treatment in renal cell carcinoma.
Authors: Dizman N, Adashek JJ, Hsu J, Bergerot PG, Bergerot CD, Pal SK Abstract In parallel with advances in the treatment of metastatic renal cell carcinoma (RCC), multiple adjuvant treatments have been tested for RCC. Adjuvant approaches now extend beyond conventional immunotherapies, such as interferon alfa and interleukins, to targeted therapies and immune checkpoint inhibitors. Most treatment approaches before the targeted treatment era did not improve patient outcomes, or study results were mixed. For example, a recent study found that disease-free survival was longer with sunitinib than with placebo in high-...
Source: Clinical Advances in Hematology and Oncology - August 29, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The evolving role of transplantation in multiple myeloma: the need for a heterogeneous approach to a heterogeneous disease.
Authors: Gandolfi S, Vekstein C, Laubach JP, O'Brien A, Masone K, Munshi NC, Anderson KC, Richardson PG Abstract Autologous stem cell transplant (ASCT) is an established frontline standard of care for the younger, fitter patients with newly diagnosed multiple myeloma (NDMM) who are eligible for the procedure, and has contributed to improved overall survival. In the current era of novel therapies, the treatment landscape and prognosis have changed. The outstanding efficacy seen with regimens based on novel agents has led to a questioning of the frontline treatment paradigm with respect to ASCT. A key current questio...
Source: Clinical Advances in Hematology and Oncology - August 29, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Bipolar androgen therapy in the treatment of prostate cancer.
Authors: Denmeade SR PMID: 30067610 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 3, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

A closer look at blinatumomab.
Authors: Mattison RJ Abstract On March 29, 2018, blinatumomab (Blincyto, Amgen) received an accelerated expanded approval for the treatment of adult and pediatric patients with B-cell precursor acute lymphoblastic leukemia (ALL) who are in first or second complete remission (CR) and have minimal residual disease (MRD). Blinatumomab was first approved for use in adult patients (in December 2014) and later in pediatric patients (in September 2016) with relapsed or refractory Philadelphia chromosome (Ph)-negative B-cell precursor ALL; the approval was expanded in July 2017 to include patients with Ph-positive disease....
Source: Clinical Advances in Hematology and Oncology - August 3, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Cellular immunotherapy for non-Hodgkin lymphoma.
Authors: Bollard C PMID: 30067612 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 3, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in kidney cancer from the American Society of Clinical Oncology Genitourinary Cancers Symposium.
Authors: Figlin RA PMID: 30067613 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 3, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Management of newly diagnosed or recurrent ovarian cancer.
Authors: Matulonis UA Abstract The treatment of newly diagnosed or recurrent ovarian cancer has changed significantly in recent years, with an increased number of treatment options available. Surgery and combination treatment with carboplatin and paclitaxel are the standard of care for patients with newly diagnosed disease, although the use of neoadjuvant chemotherapy is increasing. Clinical strategies have also evolved along with the understanding that ovarian cancer is not one disease but rather comprises several with different histologic and underlying genetic characteristics. The most common histologic type is ...
Source: Clinical Advances in Hematology and Oncology - August 3, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Contemporary management of advanced renal cell carcinoma.
Authors: Khanna A, Crane A, Yerram N, Sun D, Ericson K, Lundy SD, Abouassaly R Abstract Kidney cancer is the eighth most commonly diagnosed cancer in the United States, and nearly one-third of patients have locally advanced or metastatic disease at presentation. Historically, survival outcomes for patients with advanced disease have been poor. In recent years, several novel targeted agents have emerged for the management of advanced renal cell carcinoma that have changed treatment paradigms. At the same time, surgical therapy continues to have a critical role in the management of selected patients. Recent medical a...
Source: Clinical Advances in Hematology and Oncology - August 3, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Recent insights into large granular lymphocytic leukemia.
Authors: Nastoupil LJ PMID: 30067616 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 3, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

New and experimental agents for sickle cell disease.
Authors: Ataga KI PMID: 30067617 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 3, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Recent and ongoing clinical trials in glioblastoma.
Authors: Lombardi G PMID: 30067618 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 3, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Immunotherapy in patients who have NSCLC without EGFR or ALK mutations.
Authors: Gandhi L PMID: 30067619 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 3, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

How I treat breast cancer with positive lymph nodes.
Authors: Chagpar AB PMID: 30067620 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - August 3, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Development of poly(ADP-ribose) polymerase inhibitors in the treatment of BRCA-mutated breast cancer.
Authors: Sulai NH, Tan AR Abstract The poly(ADP-ribose) polymerases (PARPs) 1 and 2 are DNA-binding enzymes that play a critical role in the repair of DNA. The use of PARP inhibitors is a rational therapeutic approach to selectively killing a subset of cancer cells with deficiencies in DNA repair pathways. PARP inhibitors that have undergone clinical investigation in the treatment of breast cancer include olaparib, talazoparib, veliparib, niraparib, and rucaparib. The antitumor activity of PARP inhibitors as single agents has been demonstrated in BRCA-associated metastatic breast cancer. In 2018, olaparib became th...
Source: Clinical Advances in Hematology and Oncology - August 3, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Bromodomain inhibitors: what does the future hold?
Authors: Bhattacharya S, Piya S, Borthakur G Abstract Cancer cells are addicted to mutations that cause gain of function in oncogenes and loss of function in tumor suppressors, so that these cells are reliant on aberrant signaling pathways and transcription. Protein-protein and DNA-protein interactions that cause chromatin remodeling are another source of the deregulation of critical signaling and transcriptional regulators, altering epigenetic signatures and creating additional vulnerabilities. Owing to mutations in multiple epigenetic regulators in hematologic malignancies, cancer cells are highly addicted to alt...
Source: Clinical Advances in Hematology and Oncology - August 3, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Enasidenib for relapsed/refractory acute myeloid leukemia with IDH2 mutations: optimizing the patient experience.
Authors: Roboz GJ PMID: 29851927 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 1, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The evolution of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer.
Authors: Domchek SM PMID: 29851928 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 1, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

How should BRAF V600E-mutated colorectal cancer be treated?
Authors: Kopetz S PMID: 29851929 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 1, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

How I treat chemorefractory metastatic colorectal cancer.
Authors: Chu E PMID: 29851930 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 1, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Does adjuvant therapy for high-risk melanoma with either immunotherapy or targeted therapy affect therapeutic choices at relapse?
Authors: Postow MA PMID: 29851931 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 1, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Managing adverse effects of immunotherapy.
Authors: Gerson JN, Ramamurthy C, Borghaei H Abstract Remarkable efficacy has been achieved in a variety of cancer types by targeting immune checkpoints. The cytotoxic T-lymphocyte-associated antigen 4 inhibitor ipilimumab, the programmed death 1 inhibitors nivolumab and pembrolizumab, and the programmed death ligand 1 inhibitors atezolizumab, avelumab, and durvalumab are the agents currently approved by the US Food and Drug Administration for the treatment of certain advanced malignancies. These agents mark a departure from both standard cytotoxic chemotherapy and targeted therapy. However, they are associated wit...
Source: Clinical Advances in Hematology and Oncology - June 1, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphoma.
Authors: Lulla PD, Hill LC, Ramos CA, Heslop HE Abstract Resistance to conventional lines of therapy develops in approximately 20% of all patients with lymphoma. These patients have a dismal prognosis, with an expected median survival of 6.3 months. In recent years, T-cell immunotherapy has demonstrated a remarkable capacity to induce complete and durable clinical responses in patients with chemotherapy-refractory lymphoma. A major contributor to the success of immunotherapy has been the advent of genetic engineering technologies that introduce a chimeric antigen receptor (CAR) into T cells to focus their killing a...
Source: Clinical Advances in Hematology and Oncology - June 1, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in acute myeloid leukemia from the 2017 American Society of Hematology Annual Meeting and Exposition.
Authors: PMID: 29851935 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 1, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in acute myeloid leukemia from the 2017 American Society of Hematology Annual Meeting and Exposition: commentary.
Authors: DiNardo C PMID: 29851936 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 1, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Management of relapsed/refractory follicular lymphoma.
Authors: Martin P PMID: 29851937 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 1, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in cytomegalovirus from the 2018 BMT Tandem Meetings.
Authors: PMID: 29851938 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 1, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in cytomegalovirus from the 2018 BMT Tandem Meetings: commentary.
Authors: Dadwal SS PMID: 29851939 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 1, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Immunotherapy in colorectal cancer.
Authors: Le DT PMID: 29741500 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Targeted therapy for the adjuvant treatment of stage III BRAF-mutated melanoma.
Authors: Long G PMID: 29741501 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Advances in the management of primary mediastinal large B-cell lymphoma.
Authors: Advani RH PMID: 29741502 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

A closer look at copanlisib.
Authors: Dreyling M PMID: 29741503 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Research in drug development for advanced prostate cancer.
Authors: Eisenberger M PMID: 29741504 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - May 11, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research